Sanofi and Regeneron, following Amgen dropping the price of Repatha in October 2018, have dropped Praluent to $5,850 a year. This is about a 60-percent reduction from the original price for both the 75 mg and 150 mg doses.
stated Michelle Carnahan, North American Head of Primary Care Business Unit at Sanofi. “With announcement, we are looking to help bridge that gap, and have now made Praluent available at a price that is approximately 60 percent lower. We hope that payers will do their part to help ensure savings are directly passed on to more patients, through lower out-of-pocket costs.”
Sanofi and Regeneron indicate that with the newer pricing, most Medicare Part D patients will pay between $25 to $150 per month, a possible savings of up to $345, varying from insurance plan to insurance plan. The PCSK9 inhibitors, both of which were approved in 2015, are largely focused on patients who don’t respond to diet, exercise and the far more affordable statin drugs. Statins, such as Pfizer’s Lipitor, typically are priced at about $50 per month.